Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Sanne de Bruin et al.|The Lancet Rheumatology|2020Cited by 199
Clinical features and prognostic factors in Covid-19: A prospective cohort studySanne de Bruin, Marian A. van Roon, Anita M. Tuip‐de Boer et al.|EBioMedicine|2021Cited by 137
Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patientsRutger Koning, Esther J. Nossent, Paul Bastard et al.|Intensive Care Medicine|2021Cited by 132
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19Erik H Vogelzang, Lucas M. Fleuren, Floris C. Loeff et al.|The Journal of Immunology|2020Cited by 85
Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infectionLihui Guo, Robert Hemke, Brent Appelman et al.|EBioMedicine|2023Cited by 38